Drug Trial Radar · NCT07220460
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
84
Actual
Start
Sep 30, 2025
Primary completion
Mar 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Oct 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants with bipolar I or II disorder who are currently experiencing a depressive episode will enter the study and be treated with open-label ABBV-932. Approximately 200 adult participants with bipolar I or II disorder will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 for a 26-week treatment period. The treatment period will be followed by a safety follow-up (SFU) period of 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regularly scheduled visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Bipolar I or II Disorder
Interventions
ABBV-932Drug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 29 weeks
- Number of Participants with Abnormal Change From Baseline in Vital Sign MeasurementsTime frame: Up to week 26
- Number of Participants with Change from Baseline in Electrocardiogram (ECG)Time frame: Up to week 26
- Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be AssessedTime frame: Up to week 26
- Change From Baseline in Simpson-Angus Scale (SAS)Time frame: Up to week 26
- Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)Time frame: Up to week 26
- Change From Baseline in Barnes Akathisia Rating Scale (BARS)Time frame: Up to week 26
- Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to week 26
- Change From Baseline in the Epworth Sleepiness Scale (ESS)Time frame: Up to week 26
- Change From Baseline in the Young Mania Rating Scale (YMRS)Time frame: Up to week 26
- Number of Participants with Abnormal Change in Ocular ExaminationTime frame: Up to week 26
Locations
49 sites in 2 countries. Site status is shown where the registry gives one.
Ima Clinical Research Phoenix /ID# 278047
Phoenix, Arizona
Advanced Research Center /ID# 273474
Anaheim, California
Axiom Research /ID# 273482
Colton, California
Collaborative Neuroscience Research - Garden Grove /ID# 273492
Garden Grove, California
Sun Valley Research Center /ID# 273472
Imperial, California
Synergy San Diego /ID# 278340
Lemon Grove, California
Alliance for Research Alliance for Wellness /ID# 273477
Long Beach, California
Nrc Research Institute - Los Angeles /ID# 278450
Los Angeles, California
Excell Research /ID# 273483
Oceanside, California
Inland Psychiatric Medical Group /ID# 273471
Temecula, California
Sunwise Clinical Research /ID# 278165
Walnut Creek, California
Connecticut Clinical Research - Cromwell /ID# 278116
Cromwell, Connecticut
Clinical Neuroscience Solutions Healthcare - Jacksonville /ID# 278332
Jacksonville, Florida
Segal Trials - Lauderhill /ID# 273496
Lauderhill, Florida
K2 Medical Research -Maitland /ID# 273487
Maitland, Florida
GMI Florida - Central Miami Medical Institute (SMO/Network/Consortium) /ID# 273486
Miami, Florida
Allied Biomedical Res Inst Inc /ID# 273476
Miami, Florida
Floridian Clinical Research - Miami Lakes /ID# 279379
Miami Lakes, Florida
Apg Research /ID# 278439
Orlando, Florida
Health Synergy Clinical Research - West Palm Beach /ID# 279384
West Palm Beach, Florida
Trialmed /ID# 278046
Atlanta, Georgia
Atlanta Center for Medical Research /ID# 278827
Atlanta, Georgia
Revive Research Institute - Elgin /ID# 279756
Elgin, Illinois
Benchmark Research /ID# 273490
Shreveport, Louisiana
Pharmasite Research, Inc. /ID# 279163
Baltimore, Maryland
Voltaire - Springfield /ID# 278446
Springfield, Massachusetts
MSB Neuroscience /ID# 278168
Jackson, Mississippi
Arch Clinical Trials /ID# 273481
St Louis, Missouri
Alivation Research - Lincoln /ID# 279464
Lincoln, Nebraska
Ima Clinical Research Las Vegas /ID# 278054
Las Vegas, Nevada
Redbird Research /ID# 279475
Las Vegas, Nevada
Bio Behavioral Health /ID# 273478
Toms River, New Jersey
Integrative Clinical Trials /ID# 278040
Brooklyn, New York
Neurobehavioral Research /ID# 273470
Cedarhurst, New York
Ima Clinical Research - Manhattan /ID# 278941
New York, New York
New Hope Clinical Research /ID# 273468
Charlotte, North Carolina
Quest Therapeutics of Avon Lake /ID# 273484
Avon Lake, Ohio
OSU Psychiatry Department /ID# 273495
Columbus, Ohio
Sooner Clinical Research /ID# 273491
Oklahoma City, Oklahoma
Summit Research Network - Portland - Northwest Vaughn Street /ID# 278084
Portland, Oregon
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.